{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T02:11:32Z","timestamp":1778724692606,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,13]]},"DOI":"10.7759\/cureus.108814","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:57:32Z","timestamp":1778723852000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug Utilization Study and Safety Pattern of Biologicals in a Tertiary Care Hospital at Eastern India"],"prefix":"10.7759","author":[{"given":"Ravi","family":"Roushan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranshu","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saajid","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Jawed","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitesh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111694","article-title":"Biological therapies in the treatment of cancer-update and new directions","volume":"22","author":"Papie\u017c MA","year":"2021","unstructured":"Papie\u017c MA, Krzy\u015bciak W. Biological therapies in the treatment of cancer-update and new directions. Int J Mol Sci. 2021, 22:10.3390\/ijms222111694","journal-title":"Int J Mol Sci"},{"key":"ref2","unstructured":"GLOBOCAN 2020. global cancer data. (2020). Accessed: May 20, 2025: https:\/\/www.uicc.org\/news\/globocan-2020-global-cancer-data."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5603\/NJO.2015.0020","article-title":"Serendypity in a chase for a cure of cancer: Origin and perspectives of immunochemotherapy from nitrogen mustard to chimeric antygen receptors","volume":"65","author":"Walewski J","year":"2015","unstructured":"Walewski J. Serendypity in a chase for a cure of cancer: Origin and perspectives of immunochemotherapy from nitrogen mustard to chimeric antygen receptors. Nowotwory. 2015, 65:96-102. 10.5603\/NJO.2015.0020","journal-title":"Nowotwory"},{"key":"ref4","unstructured":"Biologicals. (2025). Accessed. May 20, 2025: https:\/\/www.who.int\/health-topics\/biologicals."},{"key":"ref5","article-title":"Defining the difference: what makes biologics unique","volume":"1","author":"Morrow T","year":"2004","unstructured":"Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004, 1:24-9.","journal-title":"Biotechnol Healthc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: drug costs and patient access","volume":"9","author":"Makurvet FD","year":"2021","unstructured":"Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Discovery. 2021, 9:100075. 10.1016\/j.medidd.2020.100075","journal-title":"Med Discovery"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00728","article-title":"Progress in neoantigen targeted cancer immunotherapies","volume":"8","author":"Han XJ","year":"2020","unstructured":"Han XJ, Ma XL, Yang L, Wei YQ, Peng Y, Wei XW. Progress in neoantigen targeted cancer immunotherapies. Front Cell Dev Biol. 2020, 8:728. 10.3389\/fcell.2020.00728","journal-title":"Front Cell Dev Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","volume":"18","author":"Kannaiyan R","year":"2018","unstructured":"Kannaiyan R, Mahadevan D. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther. 2018, 18:1249-70. 10.1080\/14737140.2018.1527688","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian H","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al.. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002, 346:645-52. 10.1056\/NEJMoa011573","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman PB","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al.. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364:2507-16. 10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1773","article-title":"Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer","volume":"23","author":"Khozin S","year":"2017","unstructured":"Khozin S, Weinstock C, Blumenthal GM, et al.. Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer. Clin Cancer Res. 2017, 23:2131-5. 10.1158\/1078-0432.CCR-16-1773","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)50005-1","article-title":"Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies","volume":"44","author":"Masui H","year":"1984","unstructured":"Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984, 44:1002-7. 10.1016\/S0022-5347(17)50005-1","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames P","year":"2009","unstructured":"Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009, 157:220-33. 10.1111\/j.1476-5381.2009.00190.x","journal-title":"Br J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1017\/s0025727300036632","article-title":"Monoclonal antibodies: a witness seminar in contemporary medical history","volume":"38","author":"Tansey EM","year":"1994","unstructured":"Tansey EM, Catterall PP. Monoclonal antibodies: a witness seminar in contemporary medical history. Med Hist. 1994, 38:322-7. 10.1017\/s0025727300036632","journal-title":"Med Hist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/jpgm.JPGM_109_19","article-title":"Pharmacovigilance of biosimilars - why is it different from generics and innovator biologics?","volume":"65","author":"Oza B","year":"2019","unstructured":"Oza B, Radhakrishna S, Pipalava P, Jose V. Pharmacovigilance of biosimilars - why is it different from generics and innovator biologics?. J Postgrad Med. 2019, 65:227-32. 10.4103\/jpgm.JPGM_109_19","journal-title":"J Postgrad Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2013.0478","article-title":"ICD-9-CM to ICD-10-CM codes: what? why? how?","volume":"2","author":"Cartwright DJ","year":"2013","unstructured":"Cartwright DJ. ICD-9-CM to ICD-10-CM codes: what? why? how?. Adv Wound Care (New Rochelle). 2013, 2:588-92. 10.1089\/wound.2013.0478","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0591-3","article-title":"Prevalence of use and cost of biological and non-biological targeted therapies for cancer treatment: a 5-year picture from Southern Italy","volume":"38","author":"Lucchesi S","year":"2018","unstructured":"Lucchesi S, Marcian\u00f2 I, Panagia P, et al.. Prevalence of use and cost of biological and non-biological targeted therapies for cancer treatment: a 5-year picture from Southern Italy. Clin Drug Investig. 2018, 38:269-78. 10.1007\/s40261-017-0591-3","journal-title":"Clin Drug Investig"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez A","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021, 112:90-2. 10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2010.000072","article-title":"Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice","volume":"6","author":"Hess GP","year":"2010","unstructured":"Hess GP, Wang PF, Quach D, Barber B, Zhao Z. Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract. 2010, 6:301-7. 10.1200\/JOP.2010.000072","journal-title":"J Oncol Pract"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt371","article-title":"Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer","volume":"106","author":"Abrams TA","year":"2014","unstructured":"Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst. 2014, 106:djt371. 10.1093\/jnci\/djt371","journal-title":"J Natl Cancer Inst"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2217\/cer.13.1","article-title":"Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population","volume":"2","author":"Ray S","year":"2013","unstructured":"Ray S, Bonthapally V, McMorrow D, Bonafede M, Landsman-Blumberg P. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013, 2:195-206. 10.2217\/cer.13.1","journal-title":"J Comp Eff Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6296","article-title":"Adoption of innovative therapies across oncology practices\u2014evidence from immunotherapy","volume":"9","author":"Carroll CE","year":"2023","unstructured":"Carroll CE, Landrum MB, Wright AA, Keating NL. Adoption of innovative therapies across oncology practices\u2014evidence from immunotherapy. JAMA Oncol. 2023, 9:324-33. 10.1001\/jamaoncol.2022.6296","journal-title":"JAMA Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan M","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019, 4:61. 10.1038\/s41392-019-0099-9","journal-title":"Signal Transduct Target Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.03.004","article-title":"Comparative effectiveness research: the impact of biologic agents in ethnic minorities with metastatic colorectal cancer","volume":"16","author":"Goel S","year":"2017","unstructured":"Goel S, Negassa A, Khot A, et al.. Comparative effectiveness research: the impact of biologic agents in ethnic minorities with metastatic colorectal cancer. Clin Colorectal Cancer. 2017, 16:286-92. 10.1016\/j.clcc.2017.03.004","journal-title":"Clin Colorectal Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36378","article-title":"Comparative effectiveness of biologic agents among Black and White Medicare patients in the US with metastatic colorectal cancer","volume":"4","author":"Goel S","year":"2021","unstructured":"Goel S, Negassa A, Acuna-Villaorduna A. Comparative effectiveness of biologic agents among Black and White Medicare patients in the US with metastatic colorectal cancer. JAMA Netw Open. 2021, 4:e2136378. 10.1001\/jamanetworkopen.2021.36378","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2023.10.001","article-title":"Effectiveness of biologic agents among Hispanic patients with metastatic colorectal cancer","volume":"23","author":"Patel R","year":"2024","unstructured":"Patel R, Negassa A, Tolu SS, Acuna-Villaorduna A, Goel S. Effectiveness of biologic agents among Hispanic patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2024, 23:14-21.e1. 10.1016\/j.clcc.2023.10.001","journal-title":"Clin Colorectal Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S81837","article-title":"Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer","volume":"8","author":"Zhang Q","year":"2015","unstructured":"Zhang Q, Wang Z, Guo J, et al.. Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancer. Onco Targets Ther. 2015, 8:893-8. 10.2147\/OTT.S81837","journal-title":"Onco Targets Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2013.04.005","article-title":"Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents","volume":"4","author":"Meoni G","year":"2013","unstructured":"Meoni G, Cecere FL, Lucherini E, Di Costanzo F. Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents. J Geriatr Oncol. 2013, 4:282-90. 10.1016\/j.jgo.2013.04.005","journal-title":"J Geriatr Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1409624","article-title":"Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer","volume":"18","author":"Nagasaka M","year":"2018","unstructured":"Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018, 18:63-70. 10.1080\/14737140.2018.1409624","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490763-drug-utilization-study-and-safety-pattern-of-biologicals-in-a-tertiary-care-hospital-at-eastern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:57:34Z","timestamp":1778723854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490763-drug-utilization-study-and-safety-pattern-of-biologicals-in-a-tertiary-care-hospital-at-eastern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.108814","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,13]]}}}